Innovation
8 patent families — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 78 times.
| Year | Filings |
|---|---|
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
Social engagement
Social engagement: 332 social following, 9 posts in the last 12 months — top quartile of its industry.
Investor mix
3 investors on record.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 1 | 33% |
| Other / undisclosed | 2 | 67% |
Recent activity
16 Jun 2026
Product launch
MCR-231 topical siRNA therapy engineered to temporarily silence FL2
11 Jun 2026
Product launch
pro-regenerative siRNA platform
26 May 2026
Product launch
MCR-231